Brief: Neurotech International Says European Medicines Agency Issued Positive Opinion On Orphan Medicinal Product Designation Application Of NTI164
27/02/2025 08:12
Feb 27 (Reuters) - Neurotech International Ltd NTI.AX: EUROPEAN MEDICINES AGENCY ISSUED POSITIVE OPINION ON ORPHAN MEDICINAL PRODUCT DESIGNATION APPLICATION OF NTI164 Further company coverage: NTI.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurotech International
See all newsBrief: Neurotech International Says Anthony Filippis Resigns As CEO, MD
Brief: Neurotech International Appoints Mark Davies As Executive Chairman
Brief: Neurotech International Receives Binding Commitments For Around A$4.50 Million In Placement At A$0.014 Per Share
Australia's Neurotech International slips to a month low on discounted placement
Brief: Neurotech International Requests Trading Halt